Antidiabetic alpha-glucosidase inhibitors

APX-115 (Ewha-18278) is a potent, orally active pan NADPH oxidase (Nox) inhibitor with K i values of 1.08 μM, 0.57 μM, and 0.63 μM for Nox1 , Nox2 and Nox4 , respectively. APX-115 effectively prevents kidney injuryIn VitroAPX-115 (5?μM: 60?min)

APX-115 (Ewha-18278) is a potent, orally active pan NADPH oxidase (Nox) inhibitor with K i values of 1.08 μM, 0.57 μM, and 0.63 μM for Nox1 , Nox2 and Nox4 , respectively. APX-115 effectively prevents kidney injuryIn VitroAPX-115 (5?μM: 60?min)

APX-115 (Ewha-18278) is a potent, orally active pan NADPH oxidase (Nox) inhibitor with K i values of 1.08 μM, 0.57 μM, and 0.63 μM for Nox1 , Nox2 and Nox4 , respectively. APX-115 effectively prevents kidney injuryIn VitroAPX-115 (5?μM: 60?min)

AZD1656 is a potent, selective and orally active glucokinase activator with an EC 50 of 60 nM. AZD1656 has the potential for type 2 diabetes researchIn VivoAZD1656 (0-9 mg/kg: oral gavage: daily: for 8 weeks: C57BL/6 mice) treatment shows lowered

AZD1656 is a potent, selective and orally active glucokinase activator with an EC 50 of 60 nM. AZD1656 has the potential for type 2 diabetes researchIn VivoAZD1656 (0-9 mg/kg: oral gavage: daily: for 8 weeks: C57BL/6 mice) treatment shows lowered

AZD1656 is a potent, selective and orally active glucokinase activator with an EC 50 of 60 nM. AZD1656 has the potential for type 2 diabetes researchIn VivoAZD1656 (0-9 mg/kg: oral gavage: daily: for 8 weeks: C57BL/6 mice) treatment shows lowered

Biochem/physiol Actions BEC (S-(2-boronoethyl)-l-cysteine) is a potent and specific arginase inhibitor that restores flow-induced responses in arterioles from diabetic rats. BEC is a boronic analog of L-arginine, and L-cysteine.

Biochem/physiol Actions BEC (S-(2-boronoethyl)-l-cysteine) is a potent and specific arginase inhibitor that restores flow-induced responses in arterioles from diabetic rats. BEC is a boronic analog of L-arginine, and L-cysteine.

Bilobetin, an active component of Ginkgo biloba , can reduce blood lipids and improve the effects of insulin . Bilobetin ameliorated insulin resistance, increased the hepatic uptake and oxidation of lipids, reduced very-low-density lipoprotein

Bilobetin, an active component of Ginkgo biloba , can reduce blood lipids and improve the effects of insulin . Bilobetin ameliorated insulin resistance, increased the hepatic uptake and oxidation of lipids, reduced very-low-density lipoprotein

Bilobetin, an active component of Ginkgo biloba , can reduce blood lipids and improve the effects of insulin . Bilobetin ameliorated insulin resistance, increased the hepatic uptake and oxidation of lipids, reduced very-low-density lipoprotein

A highly selective, cell-permeable, and reversible PKC inhibitor (Ki = 14 nM) acts as a competitive inhibitor for the ATP binding site of PKC and shows high selectivity for PKC&alpha-, &beta1-, &beta2-, &gamma-, &delta-, and